ATE306563T1 - Funktionaler nachweis von lipoprotein mit hoher dichte - Google Patents

Funktionaler nachweis von lipoprotein mit hoher dichte

Info

Publication number
ATE306563T1
ATE306563T1 AT01923023T AT01923023T ATE306563T1 AT E306563 T1 ATE306563 T1 AT E306563T1 AT 01923023 T AT01923023 T AT 01923023T AT 01923023 T AT01923023 T AT 01923023T AT E306563 T1 ATE306563 T1 AT E306563T1
Authority
AT
Austria
Prior art keywords
oxidised
phospholipid
mammal
high density
density lipoprotein
Prior art date
Application number
AT01923023T
Other languages
English (en)
Inventor
Alan M Fogelman
Mohamad Navab
Susan Hama
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/541,468 external-priority patent/US6596544B1/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE306563T1 publication Critical patent/ATE306563T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AT01923023T 2000-03-31 2001-03-29 Funktionaler nachweis von lipoprotein mit hoher dichte ATE306563T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53956900A 2000-03-31 2000-03-31
US09/541,468 US6596544B1 (en) 2000-03-31 2000-03-31 Functional assay of high-density lipoprotein
PCT/US2001/010592 WO2001075170A1 (en) 2000-03-31 2001-03-29 A functional assay of high-density lipoprotein

Publications (1)

Publication Number Publication Date
ATE306563T1 true ATE306563T1 (de) 2005-10-15

Family

ID=27066136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01923023T ATE306563T1 (de) 2000-03-31 2001-03-29 Funktionaler nachweis von lipoprotein mit hoher dichte

Country Status (9)

Country Link
EP (3) EP1650312A3 (de)
JP (2) JP4675539B2 (de)
AT (1) ATE306563T1 (de)
AU (3) AU2001249762B2 (de)
CA (2) CA2404000C (de)
DE (1) DE60113976T2 (de)
DK (1) DK1272666T3 (de)
ES (1) ES2250378T3 (de)
WO (2) WO2001075170A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
AU2005295640B2 (en) 2004-10-15 2011-07-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
ATE536423T1 (de) 2005-07-27 2011-12-15 Univ Graz Tech Oxidierte phospholipide mit einer fluorophorgruppierung und verwendung bei der bestimmung des vorhandenseins von enzymen mit antiatherogener aktivität
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
EP2195331B1 (de) 2007-08-28 2013-11-20 Uab Research Foundation Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
EP2826370A3 (de) 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Oxidierte Lipidverbindungen und Verwendungen davon
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3223824B1 (de) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidierte lipide und behandlung oder vorbeugung von fibrose
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
JP7084590B2 (ja) * 2016-10-31 2022-06-15 国立大学法人大阪大学 脂質異常症治療が必要な被検者の選別方法及び選別用試薬
US12055553B2 (en) 2017-03-10 2024-08-06 The Regents Of The University Of California Method for diagnosing risk for inflammatory disease through glycan profiling
US20230116567A1 (en) * 2020-02-25 2023-04-13 Lsi Medience Corporation Method for analyzing nucleic acid drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5820932Y2 (ja) * 1979-01-27 1983-05-02 財団法人杉山産業化学研究所 過酸化脂質測定のためのｔｂａ試験紙
JPS56117798A (en) * 1980-02-21 1981-09-16 Toyo Jozo Co Ltd Kit for measuring lipoid peroxide
JPS60133368A (ja) * 1983-12-19 1985-07-16 Dai Ichi Pure Chem Co Ltd 免疫測定方法
JPH01231897A (ja) * 1988-03-11 1989-09-18 Fuji Photo Film Co Ltd 乾式グルコース分析要素
US5135716A (en) * 1989-07-12 1992-08-04 Kingston Diagnostics, L.P. Direct measurement of HDL cholesterol via dry chemistry strips
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma
RU94044169A (ru) * 1994-12-16 1996-10-20 И.А. Кочетов Многослойный аналитический элемент
US5958714A (en) * 1996-10-02 1999-09-28 Safety Associates, Inc. Test kits for determining at least two specific analytes in foods and other complex matrices
AU5256398A (en) * 1996-11-15 1998-06-03 President And Fellows Of Harvard College Modulation of map kinase phosphatase 1 (mkp-1)
JP3428853B2 (ja) * 1997-04-02 2003-07-22 東北電子産業株式会社 液体試料の抗酸化力を測定するための方法および装置
EP1021728B8 (de) * 1997-06-20 2008-04-23 Leuven Research & Development VZW Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase

Also Published As

Publication number Publication date
AU4976101A (en) 2001-10-15
CA2404000C (en) 2010-07-27
DE60113976D1 (de) 2006-02-23
AU4976201A (en) 2001-10-15
CA2404000A1 (en) 2001-10-11
EP1650312A2 (de) 2006-04-26
EP1272666B1 (de) 2005-10-12
ES2250378T3 (es) 2006-04-16
WO2001075170A1 (en) 2001-10-11
DK1272666T3 (da) 2006-02-27
AU2001249762B2 (en) 2006-03-30
JP2003529375A (ja) 2003-10-07
CA2404350A1 (en) 2001-10-11
JP2003529775A (ja) 2003-10-07
EP1272666A1 (de) 2003-01-08
JP4675539B2 (ja) 2011-04-27
EP1650312A3 (de) 2006-05-17
EP1274862A4 (de) 2005-06-22
WO2001075168A1 (en) 2001-10-11
EP1274862A1 (de) 2003-01-15
DE60113976T2 (de) 2006-07-27
EP1272666A4 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
DE60113976D1 (de) Funktionaler nachweis von lipoprotein mit hoher dichte
KR970701789A (ko) 콜레스테롤의 정량방법(method for quantitatively determining cholesterol)
DK0659275T3 (da) Analytisk testapparat med indbygget negativ og positiv kontrol
DE69808071D1 (de) Nachweistest unter benutzung von magnetteilchen
ATE207542T1 (de) Testvorrichtung mit einem stabilen kopplungsfarbstoff zur bestimmung von analyten
DZ3334A1 (fr) Analyseur de glucose à réponse rapide
DE68921650D1 (de) Immunoassays.
ATA114789A (de) Verfahren und vorrichtung zur feststellung biologischer aktivitaeten in einer probe
ATE148230T1 (de) Kinetische bestimmungsmethode für endotoxin unter verwendung von limulus-amoebocyten-lysat und chromogenem substrat
ATE101722T1 (de) Qualitativer enzymtest zur visuellen auswertung.
DE60312513D1 (de) Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100
CY1105245T1 (el) Μεθοδος προεπεξepγασιας δειγματος για επιμετρηση χοληστepολης και μεθοδος επιμετρησης χοληστepολης σε συγκεκριμενες λιποπρωτεϊνες χρησιμοποιωντας αυτη τη μεθοδο
DK0797097T3 (da) Partikel-immunoassay med kompakt matrix
DE59607825D1 (de) Massensensitive Biosensoren
EP0632133A4 (de) Hochempfindliche bestimmung von d-3-hydroxybutiersäure oder acetessigsäure und zusammensetzung dafür.
DE59907982D1 (de) Verfahren zum Nachweis einer bei Apoptose aktivierten Protease
ATE360206T1 (de) Verfahren zur messung der gesamkonzentration eines analytes
DK0790494T3 (da) Flerlaget testmiddel
Feltus et al. Detection of biotin in individual sea urchin oocytes using a bioluminescence binding assay
ATE305980T1 (de) Verwendung von abfangsonden beim nachweis von nukleinsäuren
BR9914294A (pt) Dispositivo de medição da atividade enzimática de amostra alimentar sólida, sua utilização e processo de medida da atividade enzimática de um alimento
DE69017562D1 (de) Nichtspezifische adsorptionsfreie Methode zur Bestimmung eines Antikörpers und Bestimmungsreagentien.
IT1263272B (it) Test immunoenzimatico per la ricerca e la detrminazione semiquantitativa degli anticorpi anti-endotelio nel serio

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272666

Country of ref document: EP